NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets
This article was originally published in The Pink Sheet Daily
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.
You may also be interested in...
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.
SV Life Sciences and Imperial Innovations pledge up to £10 million for GSK spin-out Autifony, the second to emerge from unwanted neurosciences R&D.